1. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid
- Author
-
Fendler, A, Shepherd, STC, Au, L, Wilkinson, KA, Wu, M, Schmitt, AM, Tippu, Z, Farag, S, Rogiers, A, Harvey, R, Carlyle, E, Edmonds, K, Del Rosario, L, Lingard, K, Mangwende, M, Holt, L, Ahmod, H, Korteweg, J, Foley, T, Barber, T, Emslie-Henry, A, Caulfield-Lynch, N, Byrne, F, Shum, B, Gerard, CL, Deng, D, Kjaer, S, Song, O-R, Queval, C, Kavanagh, C, Wall, EC, Carr, EJ, Namjou, S, Caidan, S, Gavrielides, M, MacRae, JI, Kelly, G, Peat, K, Kelly, D, Murra, A, Kelly, K, O'Flaherty, M, Shea, RL, Gardner, G, Murray, D, Popat, S, Yousaf, N, Jhanji, S, Van As, N, Young, K, Furness, AJS, Pickering, L, Beale, R, Swanton, C, Crick COVID19 consortium, Gandhi, S, Gamblin, S, Bauer, DLV, Kassiotis, G, Howell, M, Nicholson, E, Walker, S, Wilkinson, RJ, Larkin, J, Turajlic, S, CAPTURE consortium, and Wellcome Trust
- Subjects
Cancer Research ,Crick COVID19 consortium ,Oncology ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,1109 Neurosciences ,CAPTURE consortium - Abstract
In this report from the CAPTURE study (NCT03226886), we demonstrate that a third dose of COVID-19 vaccine boosts neutralizing antibody (NAb) and cellular responses in patients with cancer, including those that had undetectable NAb titers (NAbT) following two vaccine doses or for whom NAbT waned. We have noted that one key member of the CAPTURE consortium—Sanjay Popat—was inadvertently not included in the author list. We now include him as a co-author. There are no additional changes to the declaration of interests statement, since Dr. Popat declares no competing conflict of interest. This author list change is now reflected in the online version of this letter.
- Published
- 2022
- Full Text
- View/download PDF